ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Average Target Price from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $77.71.

ANIP has been the subject of several analyst reports. Truist Financial upped their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. HC Wainwright restated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target for the company.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,381 shares of company stock valued at $2,441,556 over the last quarter. Company insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. KBC Group NV grew its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after buying an additional 579 shares during the period. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter worth approximately $207,000. Profund Advisors LLC acquired a new stake in ANI Pharmaceuticals in the 2nd quarter valued at approximately $225,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $228,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:ANIP opened at $58.69 on Tuesday. The company has a market capitalization of $1.23 billion, a P/E ratio of -106.71 and a beta of 0.73. The stock’s fifty day simple moving average is $56.21 and its 200-day simple moving average is $58.75. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.05 earnings per share. As a group, equities research analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.